Table 1.
Demographic and clinical characteristics.
| Variables, n (%) | Total (n = 562) | Older adults (n = 155) |
Younger adults (n = 407) | p value |
|---|---|---|---|---|
| Male | 166 (29.5) | 53 (34.2) | 113 (27.8) | 0.135 |
| Age, Median (IQR) | 52 (28–67) | 75 (69–79) | 38 (26–56) | <0.001 |
| Vaccine type | ||||
| Pfizer/BioNTech | 264 (47.0) | 82 (52.9) | 182(44.7) | |
| AstraZeneca | 225(40.0) | 71 (45.9) | 154 (37.8) | <0.001 |
| Moderna | 73 (13.0) | 2 (1.3) | 71 (17.4) | |
| Vaccine dose | ||||
| First dose | 382 (68.0) | 99 (63.9) | 283 (69.5) | 0.199 |
| Second dose | 180 (32.0) | 56 (36.1) | 124 (30.5) | |
| Initial BT ≥ 37.5 °C | 466 (82.9) | 117 (75.5) | 349 (85.7) | 0.004 |
| EMS visit to the ED | 144 (25.6) | 68 (43.9) | 76 (18.7) | <0.001 |
| Time of ED arrival | ||||
| 00:00–06:00 | 130 (23.1) | 48 (31.0) | 82 (20.1) | 0.036 |
| 06:00–12:00 | 161 (28.6) | 44 (28.4) | 117 (28.7) | |
| 12:00–18:00 | 189 (33.6) | 42 (27.1) | 147 (36.1) | |
| 18:00–00:00 | 82 (14.6) | 21 (13.5) | 61 (15.0) | |
| Comorbidities | ||||
| Hypertension | 71 (12.6) | 39 (25.2) | 32 (7.9) | <0.001 |
| Cardiovascular disease | 42 (7.5) | 29 (18.7) | 13 (3.2) | <0.001 |
| Diabetes mellitus | 37 (6.6) | 24 (15.5) | 13 (3.2) | <0.001 |
| Malignancy | 24 (4.3) | 16 (10.3) | 8 (2.0) | <0.001 |
| Respiratory disease | 10 (1.8) | 7 (4.5) | 3 (0.7) | 0.006 |
| Cerebrovascular disease | 7 (1.2) | 5 (3.2) | 2 (0.5) | 0.019 |
Values are presented as median (IQR) or numbers (%). Pfizer/BioNTech; BNT162b2, AstraZeneca; AZD1222, Moderna; mRNA-1273. BT; body temperature, ED; emergency department, EMS; emergency medical services.